These studies aim to define at a higher level of resolution the mechanism by whch the Retinal Determination Gene Network or pathway (RDGN) governs breast cancer onset and progression. Hyperactive growth factor receptor signaling remains active in many tumors that resist current therapies. The Drosophila dac gene was cloned as a dominant inhibitor of the hyperactive EGFR (Elipse). DACH1 reversed the transformed phenotype of mammary epithelial cells in 3-dimensional culture, inhibited oncogene-mediated breast tumorigenesis, blocked breast cancer epithelial cell DNA synthesis, colony formation, growth in matrigel, inhibited epithelial mesenchymal transition (EMT), tumor growth and metastasis in mice. Genetic deletion of Dach1 in the mouse results in perinatal lethality therefore we developed conditional Dach1 knockout tri- transgenic systems. Our studies provide support for a model in which DACH1 physical interactions with specific proteins coordinate DACH1-tumor suppression. These interactions govern growth suppression in breast tumor genetic subtype specific manner. DACH1 binds p53 to enhance p53 tumor suppressor functions. DACH1 binds and inhibits the function of growth inducing proteins through distinct mechanisms (YB-1, EYA1, FKHR) (Fig. 1). These studies will further characterize a novel tumor and metastasis suppressor pathway. We hypothesize that inactivation of the DACH1/EYA pathway is a key signaling event contributing to mammary tumorigenesis and metastasis. We will determine the mechanism by which DACH1 inhibits breast tumor cellular proliferation and metastasis in vivo. Photo-uncaging to induce single cell level Cre excision will allow determination of sister cell interactions and the in vivo significance of a new model of tumor suppression. Functional analyses of DACH1-secreted factors and synthetic lethal screens will identify new cancer targets.

Public Health Relevance

Breast cancer is the second commonest cause of cancer death in women in the United States, and therapy resistance is driven in part by the expansion of breast tumor stem cells (BTSC). We have shown that Dach1, a component of the Retinal Determination Gene Network (RDGN), inhibits governs breast cancer tumor growth and BTSC. These studies aim to identify breast cancer secreted factors and small molecule inhibitors which govern breast cancer stem cell expansion to form the basis of a novel approach to breast cancer treatment.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
2R01CA132115-05A1
Application #
8697542
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Woodhouse, Elizabeth
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Thomas Jefferson University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Zhao, Qian; Deng, Shengqiong; Wang, Guangxue et al. (2016) A direct quantification method for measuring plasma MicroRNAs identified potential biomarkers for detecting metastatic breast cancer. Oncotarget 7:21865-74
Ozcan, Lale; Ghorpade, Devram S; Zheng, Ze et al. (2016) Hepatocyte DACH1 Is Increased in Obesity via Nuclear Exclusion of HDAC4 and Promotes Hepatic Insulin Resistance. Cell Rep 15:2214-25
Casimiro, Mathew C; Di Sante, Gabriele; Ju, Xiaoming et al. (2016) Cyclin D1 Promotes Androgen-Dependent DNA Damage Repair in Prostate Cancer Cells. Cancer Res 76:329-38
Wu, Kongming; Yuan, Xun; Pestell, Richard (2015) Endogenous Dach1 in cancer. Oncoscience 2:803-4
Xu, Hanxiao; Tian, Yijun; Yuan, Xun et al. (2015) The role of CD44 in epithelial-mesenchymal transition and cancer development. Onco Targets Ther 8:3783-92
Sun, X; Jiao, X; Pestell, T G et al. (2014) MicroRNAs and cancer stem cells: the sword and the shield. Oncogene 33:4967-77
Wu, Kongming; Chen, Ke; Wang, Chenguang et al. (2014) Cell fate factor DACH1 represses YB-1-mediated oncogenic transcription and translation. Cancer Res 74:829-39
Velasco-Velázquez, Marco; Xolalpa, Wendy; Pestell, Richard G (2014) The potential to target CCL5/CCR5 in breast cancer. Expert Opin Ther Targets 18:1265-75
Yu, Zuoren; Xu, Zengguang; Disante, Gabriele et al. (2014) miR-17/20 sensitization of breast cancer cells to chemotherapy-induced apoptosis requires Akt1. Oncotarget 5:1083-90
Sicoli, Daniela; Jiao, Xuanmao; Ju, Xiaoming et al. (2014) CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines. Cancer Res 74:7103-14

Showing the most recent 10 out of 24 publications